Skip to main content
Premium Trial:

Request an Annual Quote

Celera Sees Slightly Stronger Revenue, Narrowed Loss in Q4

NEW YORK, July 25 - Celera Genomics today said that its fiscal fourth-quarter loss narrowed as the severe staff cutsimplemented last month to help push the company downstream began to pay off.

Revenue in the period ended June 30 inched up to $28.1 million from $27.4 million one year ago. Receipts from Celera's online business, which the company has been gradually divesting, increased to $19.8 million from $14.2 million in the year-ago quarter.


However, Celera said the increase was offset by lower contract sequencing revenue resulting from the company's decision not to pursue additional "non-strategic service business."

As a result,net loss in the quarter decreased to $28.8 million, or $.42 per share, from $101.7 million, or $1.66 per share, one year ago.
Looking ahead, Celera said that fiscal 2003 revenue will likely fall to between $85 million and $95 million, down from $120.9 million in 2002.

Celera also said it expects R&D spending to range between $130 million and $140 million. The company said that roughly 65 percent of that spending will go to drug discovery and development.


Celera reported approximately $889 million in cash and short-term investments at the end of its fiscal year, which concluded June 30. The number represents $107 million less than the company's cash and short-term holdings at the same time last year. Celera spokesman Robert Bennett said that by end of fiscal 2003, that number will be cut by an additional $75 million to $85 million.


Click here for more information.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.